Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).

Int J Endocrinol · 2013 · PMC3755443 · PMID 23997767

Europe PMC DOI

hedged sentence

0.1160

closest p · 2.3× alpha

0.1160

boldest claim

The sentences

did not reach statistical significanceP = 0.116not close (p > 0.1)

Concerning DBP, a statistically significant decrease was found in the T group (86.0 ± 8.5 versus 75.4 ± 12.7 mmHg ( P = 0.032)), whereas the decrease in the L group did not reach statistical significance (81.6 ± 13.0 versus 75.3 ± 7.9 mmHg ( P = 0.116)) ( Table 2 ). 3.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.